Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection

ABSTRACT The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric prote...

Full description

Bibliographic Details
Main Authors: Shaohui Wang, Duolong Zhu, Xingmin Sun
Format: Article
Language:English
Published: American Society for Microbiology 2022-06-01
Series:Microbiology Spectrum
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/spectrum.00263-22
_version_ 1828833214940053504
author Shaohui Wang
Duolong Zhu
Xingmin Sun
author_facet Shaohui Wang
Duolong Zhu
Xingmin Sun
author_sort Shaohui Wang
collection DOAJ
description ABSTRACT The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein (designated Tcd169), comprised of the glucosyltransferase domain (GT), the cysteine protease domain (CPD), and the receptor binding domain (RBD) of TcdB, and the RBD of TcdA. Parenteral immunizations with Tcd169 provide mice effective protection against infection with a ribotype (RT) 027 C. difficile strain. In this study, we expressed Tcd169 in a nontoxigenic C. difficile CCUG37785 strain (designated NTCD), resulting in strain NTCD_Tcd169 to develop an oral vaccine that can target both C. difficile toxins and colonization/adhesion factors. Oral immunizations with NTCD_Tcd169 spores induced systematic and mucosal antibody responses against, not only both toxins, but also C. difficile flagellins (FliC/FliD). Intriguingly yet importantly, anti-Tcd169 sera raised against Tcd169 protein were significantly cross-reactive with FliC/FliD and two surface layer proteins (SlpA and Cwp2). Oral immunizations with NTCD_Tcd169 spores provided mice effective protection against infection with a hypervirulent RT027 C. difficile strain R20291and significantly reduced R20291spore numbers in feces compared with NTCD or PBS immunized mice. These results imply that the genetically modified, nontoxigenic C. difficile strain expressing Tcd169 may represent a novel mucosal vaccine candidate against CDI. IMPORTANCE Clostridioides difficile is an enteric pathogen, and symptoms of C. difficile infection (CDI) are mainly by two exotoxins TcdA and TcdB. Active vaccination is cost-effective approach to prevent CDI and high rates of recurrence. Ideally, vaccines should target both C. difficile toxins and cell/spore colonization. In this study, we expressed immunodominant fragments of TcdA and TcdB (i.e., Tcd169) in a nontoxigenic C. difficile CCUG37785 strain, generating a promising oral/mucosal vaccine candidate against CDI, by targeting both toxins and colonization of pathogenic C. difficile strains. Importantly, anti-Tcd169 sera raised against Tcd169 protein were significantly cross-reactive with FliC/FliD and two surface layer proteins (SlpA and Cwp2), and all of which are involved in C. difficile adhesion/colonization in vitro and in vivo.
first_indexed 2024-12-12T17:13:42Z
format Article
id doaj.art-bbb97c1c4bd343128096d485bd97fdbc
institution Directory Open Access Journal
issn 2165-0497
language English
last_indexed 2024-12-12T17:13:42Z
publishDate 2022-06-01
publisher American Society for Microbiology
record_format Article
series Microbiology Spectrum
spelling doaj.art-bbb97c1c4bd343128096d485bd97fdbc2022-12-22T00:17:50ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972022-06-0110310.1128/spectrum.00263-22Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile InfectionShaohui Wang0Duolong Zhu1Xingmin Sun2Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USADepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USADepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USAABSTRACT The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein (designated Tcd169), comprised of the glucosyltransferase domain (GT), the cysteine protease domain (CPD), and the receptor binding domain (RBD) of TcdB, and the RBD of TcdA. Parenteral immunizations with Tcd169 provide mice effective protection against infection with a ribotype (RT) 027 C. difficile strain. In this study, we expressed Tcd169 in a nontoxigenic C. difficile CCUG37785 strain (designated NTCD), resulting in strain NTCD_Tcd169 to develop an oral vaccine that can target both C. difficile toxins and colonization/adhesion factors. Oral immunizations with NTCD_Tcd169 spores induced systematic and mucosal antibody responses against, not only both toxins, but also C. difficile flagellins (FliC/FliD). Intriguingly yet importantly, anti-Tcd169 sera raised against Tcd169 protein were significantly cross-reactive with FliC/FliD and two surface layer proteins (SlpA and Cwp2). Oral immunizations with NTCD_Tcd169 spores provided mice effective protection against infection with a hypervirulent RT027 C. difficile strain R20291and significantly reduced R20291spore numbers in feces compared with NTCD or PBS immunized mice. These results imply that the genetically modified, nontoxigenic C. difficile strain expressing Tcd169 may represent a novel mucosal vaccine candidate against CDI. IMPORTANCE Clostridioides difficile is an enteric pathogen, and symptoms of C. difficile infection (CDI) are mainly by two exotoxins TcdA and TcdB. Active vaccination is cost-effective approach to prevent CDI and high rates of recurrence. Ideally, vaccines should target both C. difficile toxins and cell/spore colonization. In this study, we expressed immunodominant fragments of TcdA and TcdB (i.e., Tcd169) in a nontoxigenic C. difficile CCUG37785 strain, generating a promising oral/mucosal vaccine candidate against CDI, by targeting both toxins and colonization of pathogenic C. difficile strains. Importantly, anti-Tcd169 sera raised against Tcd169 protein were significantly cross-reactive with FliC/FliD and two surface layer proteins (SlpA and Cwp2), and all of which are involved in C. difficile adhesion/colonization in vitro and in vivo.https://journals.asm.org/doi/10.1128/spectrum.00263-22nontoxigenic Clostridioides difficileClostridioides difficile infectionchimeric proteinvaccinesporeoral immunization
spellingShingle Shaohui Wang
Duolong Zhu
Xingmin Sun
Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
Microbiology Spectrum
nontoxigenic Clostridioides difficile
Clostridioides difficile infection
chimeric protein
vaccine
spore
oral immunization
title Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
title_full Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
title_fullStr Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
title_full_unstemmed Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
title_short Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
title_sort development of an effective nontoxigenic clostridioides difficile based oral vaccine against c difficile infection
topic nontoxigenic Clostridioides difficile
Clostridioides difficile infection
chimeric protein
vaccine
spore
oral immunization
url https://journals.asm.org/doi/10.1128/spectrum.00263-22
work_keys_str_mv AT shaohuiwang developmentofaneffectivenontoxigenicclostridioidesdifficilebasedoralvaccineagainstcdifficileinfection
AT duolongzhu developmentofaneffectivenontoxigenicclostridioidesdifficilebasedoralvaccineagainstcdifficileinfection
AT xingminsun developmentofaneffectivenontoxigenicclostridioidesdifficilebasedoralvaccineagainstcdifficileinfection